Figure 5
Figure 5. RAP-011 can restore erythroid levels in ribosome-deficient embryos. (A) Rpl11 morpholino-injected embryos were treated with IgG or RAP-011. Staining of 48 hpf embryos with o-Dianisidine shows a partial recovery (seen in ∼87.0% of embryos; P < .05) of globin-positive cells (arrows). (B) In situ hybridization for PCNA expression in morpholino-injected embryos, 24 hpf, treated with IgG or RAP-011. Rescue by PCNA staining seen in ∼87.2% of embryos; P < .05. (C-D) o-Dianisidine staining of RPL11 or RPS19-mutant embryos treated with RAP-011. Observed phenotype (A): Rpl11 MO + IgG = 32/32 Rpl11 MO + RAP-011 = 54/62; (B): Rpl11 MO + IgG = 58/58 Rpl11 MO + RAP-011 = 41/47; (C): Rpl11(−/−) = 15/15 Rpl11(−/−) + RAP-011 = 10/10; (D): Rps19(−/−) = 8/8 Rps19(−/−) + RAP-011 = 12/12.

RAP-011 can restore erythroid levels in ribosome-deficient embryos. (A) Rpl11 morpholino-injected embryos were treated with IgG or RAP-011. Staining of 48 hpf embryos with o-Dianisidine shows a partial recovery (seen in ∼87.0% of embryos; P < .05) of globin-positive cells (arrows). (B) In situ hybridization for PCNA expression in morpholino-injected embryos, 24 hpf, treated with IgG or RAP-011. Rescue by PCNA staining seen in ∼87.2% of embryos; P < .05. (C-D) o-Dianisidine staining of RPL11 or RPS19-mutant embryos treated with RAP-011. Observed phenotype (A): Rpl11 MO + IgG = 32/32 Rpl11 MO + RAP-011 = 54/62; (B): Rpl11 MO + IgG = 58/58 Rpl11 MO + RAP-011 = 41/47; (C): Rpl11(−/−) = 15/15 Rpl11(−/−) + RAP-011 = 10/10; (D): Rps19(−/−) = 8/8 Rps19(−/−) + RAP-011 = 12/12.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal